Vagus nervestimulering for moderat til alvorlig revmatoid artritt (RESET-RA)
Vagus nervestimulering ved bruk av SetPoint-systemet for moderat til alvorlig revmatoid artritt: RESET-RA-studien
The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
The RESET-RA study is an operationally seamless, 2-stage, randomized, double-blind, sham-controlled, multicenter pivotal study enrolling up to 250 subjects at up to 45 study centers across the U.S. The study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis (RA) who have had an inadequate response, loss of response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). The implant delivers a small amount of electricity (stimulation) to the nerve. All eligible subjects will undergo the surgery under general anesthesia. Half of the subjects will receive active stimulation (the treatment group) and the other half will receive non-active stimulation (the control group). Stimulation will be delivered for 1 min once per day for 12 weeks. After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety. Blinding will be maintained until the last enrolled and randomized subject in Stage 2 completes Week 12 assessments, and the study database is locked.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Mesa, Arizona, Forente stater, 85210
- Arizona Arthritis ans Rheumatology Research, PPLC
-
Phoenix, Arizona, Forente stater, 85037
- Arizona Arthritis Rheumatology & Research, PLLC
-
Tucson, Arizona, Forente stater, 85704
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Covina, California, Forente stater, 91722
- Medvin Clinical Research
-
Upland, California, Forente stater, 91786
- Inland Rheumatology Clinical Trials
-
Whittier, California, Forente stater, 90602
- Medvin Clinical Research
-
-
Colorado
-
Fort Collins, Colorado, Forente stater, 80528
- The Arthritis & Rheumatology Clinic of Northern Colorado
-
-
Connecticut
-
Stamford, Connecticut, Forente stater, 06905
- Stamford Therapeutics Consortium
-
-
Delaware
-
Lewes, Delaware, Forente stater, 19958
- Delaware Arthritis
-
-
Florida
-
Aventura, Florida, Forente stater, 33180
- Arthritis & Rheumatic Disease Specialties
-
Avon Park, Florida, Forente stater, 33825
- HARAC Research Corporation
-
Boynton Beach, Florida, Forente stater, 33472
- RecioMed Clinical Research Network, Inc.
-
Clearwater, Florida, Forente stater, 33765
- Bay Area Rheumatology
-
Plantation, Florida, Forente stater, 33324
- IRIS Research and Development
-
-
Georgia
-
Augusta, Georgia, Forente stater, 30912
- Augusta University
-
Lawrenceville, Georgia, Forente stater, 30044
- Parris and Associates Rheumatology
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
Willowbrook, Illinois, Forente stater, 60527
- Willow Rheumatology and Wellness PLLC
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital Division of Rheumatology, Allergy, and Immunology
-
-
Michigan
-
Lansing, Michigan, Forente stater, 48910
- June DO, PC
-
-
Minnesota
-
Eagan, Minnesota, Forente stater, 55121
- Saint Paul Rheumatology, P.A.
-
-
Missouri
-
Kansas City, Missouri, Forente stater, 64151
- Kansas City Physician Partners
-
St Louis, Missouri, Forente stater, 63122
- West County Rheumatology
-
-
Nebraska
-
Lincoln, Nebraska, Forente stater, 68516
- Physician Research Collaboration, LLC
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87102
- Albuquerque Center for Rheumatology
-
-
New York
-
Babylon, New York, Forente stater, 11702
- Long Island Regional Arthritis & Osteoporosis Care
-
-
North Carolina
-
Charleston, North Carolina, Forente stater, 28202
- Arthritis & Osteoporosis Consultants Of The Carolinas
-
Charlotte, North Carolina, Forente stater, 28210
- DJL Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73103
- Health Research of Oklahoma, PLLC
-
Oklahoma City, Oklahoma, Forente stater, 73116
- Rheumatology Associates of Oklahoma
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Lehigh Valley Health Network
-
Philadelphia, Pennsylvania, Forente stater, 19104
- University of Pennsylvania Medical Center
-
-
Texas
-
Allen, Texas, Forente stater, 75013
- Arthritis & Rheumatology Research Institute, PLLC
-
Austin, Texas, Forente stater, 78745
- Tekton Research
-
Austin, Texas, Forente stater, 78717
- Austin Regional Clinic
-
Austin, Texas, Forente stater, 78746
- Central Texas Rheumatology Associates
-
Colleyville, Texas, Forente stater, 76034
- Precision Comprehensive Clinical Research Solutions
-
Houston, Texas, Forente stater, 77043
- Biopharma Informatic
-
Mesquite, Texas, Forente stater, 75150
- Southwest Rheumatology Research LLC
-
San Antonio, Texas, Forente stater, 78229
- Clinical Trials of Texas, Inc
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22033
- Annapolis Rheumatology
-
-
Washington
-
Bothell, Washington, Forente stater, 98021
- Sound Clinical Research, LLC
-
-
West Virginia
-
Morgantown, West Virginia, Forente stater, 26506
- West Virginia University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 22-75 years of age at screening
- Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints
- Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)
- Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12
Exclusion Criteria:
- Untreated or poorly controlled psychiatric illness or history of substance abuse
- Significant immunodeficiency due to underlying illness
- History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia
- Clinically significant cardiovascular disease
- Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease
- Uncontrolled fibromyalgia
- History of left or right carotid surgery
- History of unilateral or bilateral vagotomy, partial or complete splenectomy
- Recurrent vasovagal syncope episodes
- Current, regular use of tobacco products
- Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Treatment
Active stimulation for 1 min once per day |
The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
Andre navn:
All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
Andre navn:
Active stimulation for 1 min once per day |
|
Sham-komparator: Control
Non-active stimulation for 1 min once per day |
The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
Andre navn:
All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
Andre navn:
Non-active stimulation for 1 min once per day |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
the American College of Rheumatology (ACR) 20 Response
Tidsramme: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
DAS28-CRP Good or Moderate Response as Defined by European League Against Rheumatism (EULAR)
Tidsramme: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) good or moderate response as defined by EULAR based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 A subject is considered having a moderate treatment response if:
A subject is considered having a good treatment response if: • DAS28-CRP score improvement from baseline to Week 12 is > 1.2 and the DAS28-CRP score at Week 12 is ≤ 3.2 |
Week 12
|
|
DAS28-CRP Response (MCID -1.2) at Week 12
Tidsramme: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) response is based on the minimal clinically important difference (MCID) of -1.2 from baseline. DAS28-CRP is based on a composite score of 4 items: tender and swollen joint counts of 28 joints (scale 0=best to 28=worst), subject global assessment (0=best to 10=worst) and high-sensitivity C-reactive protein (hsCRP) concentration (mg/L). A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 |
Week 12
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22)
Tidsramme: Week 12
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 12
|
|
ACR20 Response at Week 12 From Day 0
Tidsramme: Week 12
|
Response is defined as achieving at least 20% improvement from Day 0 to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worse), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/mL). |
Week 12
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Bone Erosion Progression, All Completers
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Bone Erosion Progression, All Completers With Erosive Phenotype
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Bone Erosion Progression, All Completers That Previously Only Failed 1 b/tsDMARD
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand. A total score for each pathology is generated by the summation of individual joint/bone scores as follows:
The proportion of bone erosion progressors is the % subjects with an increase of > 0.5 on the bone erosion score, comparing baseline to Week 12. An increase of > 0.5 represents disease progression. |
Week 12
|
|
Change in Erosion Score, All Completers
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Erosion Score, All Completers With Erosive Phenotype
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Erosion Score, All Completers That Previously Only Failed 1 b/tsDMARD
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Bone erosion: 25 bones each scored on a scale from 0 (0-10% eroded volume) to 10 (91-100% eroded volume), resulting in a total score from 0 to 250. |
Week 12
|
|
Change in Synovitis Score, All Completers
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Synovitis Score, All Completers With Erosive Phenotype
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Synovitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Synovitis: 8 joints each scored on a scale from 0 = normal to 3 = severe, resulting in a total score from 0 to 24. |
Week 12
|
|
Change in Osteitis Score, All Completers
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Change in Osteitis Score, All Completers With Erosive Phenotype
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Change in Osteitis Score, All Completers That Previously Only Failed 1 b/tsDMARD
Tidsramme: Week 12
|
RAMRIS is a standardized system for RA MRI scoring of 4 different types of joint pathologies in the wrist and the hand (synovitis, bone erosion, osteitis, and cartilage loss). A total score for each pathology is generated by the summation of individual joint/bone scores: • Osteitis: 25 bones scored on a scale from 0 (no osteitis) to 3 (68-100% of bone volume involved), resulting in a total score from 0 to 75. |
Week 12
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission
Tidsramme: Week 12
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 12
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission
Tidsramme: Week 12
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Tidsramme: Week 24
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 24
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Tidsramme: Week 24
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 24
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Tidsramme: Week 24
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 24
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Tidsramme: Week 24
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 24
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Tidsramme: Week 24
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 24
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Tidsramme: Week 24
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 24
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Tidsramme: Week 24
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 24
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Tidsramme: Week 24
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 24
|
|
Study Participants That Are Somewhat to Very Satisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Tidsramme: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Are Neither Satisfied Nor Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Tidsramme: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Are Somewhat to Very Dissatisfied With the SetPoint System for Treatment of Rheumatoid Arthritis
Tidsramme: Week 24
|
Patient satisfaction was assessed at Week 24 using five-point Likert rating scale:
|
Week 24
|
|
Study Participants That Would Recommend the SetPoint System to a Family Member or Friend
Tidsramme: Week 24
|
Patients were asked a question about whether they would recommend the SetPoint System to family and friends |
Week 24
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Tidsramme: Week 36
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 36
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Tidsramme: Week 36
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 36
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Tidsramme: Week 36
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 36
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Tidsramme: Week 36
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 36
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Tidsramme: Week 36
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 36
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Tidsramme: Week 36
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 36
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Tidsramme: Week 36
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 36
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Tidsramme: Week 36
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 36
|
|
the American College of Rheumatology (ACR) 20 Response, All Completers
Tidsramme: Week 48
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 48
|
|
the American College of Rheumatology (ACR) 20 Response, Non-augmented
Tidsramme: Week 48
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 48
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, All Completers
Tidsramme: Week 48
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 48
|
|
Clinical Disease Activity Index (CDAI) Low Disease Activity (LDA) or Remission, Non-augmented
Tidsramme: Week 48
|
The CDAI score is based on 4 items:
The CDAI score is calculated as follows and ranges from 0 to 76: • CDAI = TJC28 + SJC28 + SGA + EGA The CDAI score corresponds to the current RA activity:
|
Week 48
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, All Completers
Tidsramme: Week 48
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 48
|
|
DAS28-CRP Low Disease Activity (LDA) or Remission, Non-augmented
Tidsramme: Week 48
|
The Disease Activity Score in 28 joints calculated with C-reactive protein (DAS28-CRP) score is a composite index providing a measure of disease activity, comprising:
A total score ranges from 0 to 10 and is computed as follows: DAS28-CRP = 0.56 * sqrt(TJC28) + 0.28 * sqrt(SJC28) + 0.36 * ln(CRP+1) + 0.014 * SGA + 0.96 The DAS28-CRP score corresponds to the current RA activity:
|
Week 48
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) MCID Response, All Completers
Tidsramme: Week 48
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 48
|
|
Health Assessment Questionnaire Disability Index (HAQ-DI) Response (MCID -0.22), Non-augmented
Tidsramme: Week 48
|
HAQ-DI response based on the MCID of -0.22 from baseline. The HAQ-DI is a questionnaire validated for RA self-assessment by subjects that contains 20 questions in the following 8 functional areas:
Scoring within each functional area is from 0 (without any difficulty) to 3 (unable to do). The total score is obtained by summing 8 area scores and dividing by 8. The total HAQ-DI score ranges from 0 to 3 and corresponds to the current degree of disability:
|
Week 48
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 1 Prior b/tsDMARD
Tidsramme: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 2 Prior b/tsDMARD
Tidsramme: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With 3 Prior b/tsDMARD
Tidsramme: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
|
the American College of Rheumatology (ACR) 20 Response, Subjects With >=4 Prior b/tsDMARD
Tidsramme: Week 12
|
Response is defined as achieving at least 20% improvement from baseline to Week 12 in tender and swollen joint counts of 28 joints (scale 0=best to 28=worst) and 3 out of the following 5 measures: Health Assessment Questionnaire Disability Index (HAQ-DI) score (scale 0=no difficulty to 3=unable to do), subject global assessment (0=best to 10=worst), subject pain (0=no pain to 10=worst), evaluator's global assessment (0=best to 10=worst), or high sensitivity C-reactive protein (hsCRP) concentration (mg/L). |
Week 12
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Mark Richardson, MD PhD, Massachusetts General Hospital
- Hovedetterforsker: John Tesser, MD, Arizona Arthritis and Rheumatology Research, P.C.
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Peterson D, Van Poppel M, Boling W, Santos P, Schwalb J, Eisenberg H, Mehta A, Spader H, Botros J, Vrionis FD, Ko A, Adelson PD, Lega B, Konrad P, Calle G, Vale FL, Bucholz R, Richardson RM. Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study. Bioelectron Med. 2024 Mar 13;10(1):8. doi: 10.1186/s42234-023-00138-x.
- Tesser JRP, Crowley AR, Box EJ, June JP, Wickersham PB, Valenzuela GJ, Gaylis NB, Lam GKW, Pacheco LA, Ridley DJ, Pinto-Patarroyo GP, Novack SN, Churchill MA, Kohler M, Lee EC, Pando JA, Parris GR, Peterson JR, Shah T, Singhal AK, Vuong V, Levine YA, Evangelista ML, Derosier AA, Curtis JR, Richardson RM, Chernoff D. Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nat Med. 2026 Jan;32(1):369-378. doi: 10.1038/s41591-025-04114-7. Epub 2025 Dec 22.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- SPM-020
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
No sharing data is planned.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .